Difference between revisions of "Globalisation:National Obesity Forum"
(→Funding) |
(→Sources) |
||
| Line 49: | Line 49: | ||
[[Funding]] | [[Funding]] | ||
| − | |||
| − | |||
==Views on tackling obesity== | ==Views on tackling obesity== | ||
Revision as of 18:43, 19 October 2010
Emma Patrick Christina McDonald Rachel Cunningham
http://www.nationalobesityforum.org.uk/
History
The National Obesity Forum was created in 2000 by a group of health professionals and is a registered charity (1109600).
The main aims of the NOF are to:
-Increase the public focus on obesity and develop more awareness about the health implications.
-To help educate more people on the topic of obesity and health from an earlier age.
-To encourage the Government to make tackling obesity a priority, in order to save the NHS money in future years.
People
Trustees
- Dr Hilary Jones Patron
- Jane DeVille-Almond Vice Chair
- Dr David Haslam - GP, Hertfordshire Chair
- Shamil Chandaria - Honorary Patron
- Anne Diamond Honorary - Patron
- Dr Matthew Capehorn - Clinical Director
- Tam Fry - Honorary Chairman of The Child Growth Foundation
- Paul Sacher - Research Director, MEND Programme
- Dr Colin Waine - Patron
National Obesity Forum Trustees
Views on tackling obesity
The National Obesity Forum advocate many ways of tackling obesity.
-They advise increasing activity levels, and put importance on making exercise ‘fun’ and easy by focussing on ordinary activities such as gardening, shopping, and sports.
-They also advise making a personal plan to suit each individual.
-They provide information on how to have a healthy diet and put importance on portion control.
- Advice is also given on 'positive thinking' and how this can impact a person's ability to lose weight.
The NOF also back more drastic and often risky means of weight loss, including; very low calorie diets, medication, meal replacements, and even surgery.
With regards to weight loss medication (or 'Anti-Obesity Medication), the NOF mention two specific drugs - Sibutramine(Reductil) and Orlistat(Alli).
One of these drugs - Orlistat - was actually the first 'over the counter' weight loss drug available, and was produced by Glaxosmithkline, which is one of the NOFs parter organisations. [1]
Notes
- ↑ Orlistat, "Overweight and Obese Treatment - GlaxoSmithKline Receieves European Commission to Market Alli", Orlistat, 21 January 2009, accessed 19 October 2010
